Keywords: موکوپلیساکاریدوز; Juvenile idiopathic arthritis; Arthropathy; Multicentric osteolysis; Mucopolysaccharidosis; Dsyplasia;
مقالات ISI موکوپلیساکاریدوز (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: موکوپلیساکاریدوز; Enfermedades raras; Enfermedades metabólicas hereditarias; Enfermedades genéticas; Mucopolisacaridosis; Niños con necesidades especiales; Transición; Rare diseases; Hereditary metabolic diseases; Genetic diseases; Mucopolysaccharidosis; Children with
Keywords: موکوپلیساکاریدوز; Rare diseases; Hereditary metabolic diseases; Genetic diseases; Mucopolysaccharidosis; Children with special needs; Transition; Enfermedades raras; Enfermedades metabólicas hereditarias; Enfermedades genéticas; Mucopolisacaridosis; Niños con necesidade
Keywords: موکوپلیساکاریدوز; MPS; mucopolysaccharidosis; LSD; pain; pain management; storage disease; pain treatment;
Keywords: موکوپلیساکاریدوز; biomarkers; disease progression; mucopolysaccharidosis type III B; prospective study; BSID-III; Bayley Scales of Infant Development, Third Edition; CHQ-PF50; Child Health Questionnaire Parent Form, 50 items; CSF; Cerebrospinal fluid; DQ; Development quoti
Keywords: موکوپلیساکاریدوز; Non-immune hydrops fetalis; fetal hydrops; fetal therapy; fetal metabolism; AF; amniotic fluid; CBC; complete blood count; CMV; cytomegalovirus; DNA; deoxyribonucleic acid; ELISA; enzyme-linked immunosorbent assay; FISH; fluorescent in situ hybridization;
Keywords: موکوپلیساکاریدوز; CNS; central nervous system; ERT; Enzyme replacement therapy; HCT; hematopoietic cell transplantation; MPS; Mucopolysaccharidosis; MPS I; Mucopolysaccharidosis Type I; MPS IH; Mucopolysaccharidosis Type IH, Hurler Syndrome; MRI; magnetic resonance imaging
Keywords: موکوپلیساکاریدوز; CK; Creatine kinase; DBS; Dried blood spot; GAA; Alpha-glucosidase; GAG; Glycosaminoglycan; GBA; Beta-glucosidase; IDUA; Alpha-L-iduronidase; IOPD; Infantile-onset Pompe disease; LOPD; Late-onset Pompe disease; LSD; Lysosomal storage disorder; MPS; Mucopo
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; MPS; Cardiovascular risk; Cholesterol; Lipids; Diabetes; BMI;
Keywords: موکوپلیساکاریدوز; AD; axial diffusivity; CNS; central nervous system; CSF; cerebrospinal fluid; DTI; diffusion tensor imaging; FA; fractional anisotropy; FLAIR; fluid-attenuated inversion recovery; GAG; glycosaminoglycan; GM; gray matter; HCP; human connectome project; MD;
Keywords: موکوپلیساکاریدوز; Pediatric carpal tunnel; carpal tunnel syndrome; Hurler syndrome; mucopolysaccharidosis; enzyme replacement therapy;
Keywords: موکوپلیساکاریدوز; MPS; mucopolysaccharidosis; GAG; glycosaminoglycang; CS; chondroitin sulfate; DS; dermatan sulfate; HS; heparan sulfate; KS; keratan sulfate; ECM; extracellular matrix; IDUA; α-l-iduronidase; I2S; iduronate-2-sulfatse; SGHS; heparan-N-sulfatase; NAGLU; Î
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidoses; Lysosomal storage diseases; Behavior; Child behavior disorders; Mental disorders; CNS; central nervous system; GAG; glycosaminoglycan; MPS; mucopolysaccharidosis; MPS IH; Hurler syndrome; T-DSM-IV-S; Turgay Diagnostic and Statistica
Keywords: موکوپلیساکاریدوز; AFM; atomic force microscopy; APC; antigen-presenting cell; CNE; cationic nanoemulsion; COL; cholesterol; CTAB; cetyltrimethylammonium bromide; DC-Chol; 3-b[N-(N0,N0-dimethylaminoethane)-carbamoyl] cholesterol; DDA; dimethyldioctadecylammonium (bromide sa
Keywords: موکوپلیساکاریدوز; AAV; adeno-associated viruses; AE; adverse event; BBB; blood-brain barrier; CLN2; ceroid lipofuscinosis neuronal type 2; CNS; central nervous system; CSF; cerebrospinal fluid; DQ; developmental quotient; ERT; enzyme replacement therapy; g7; 7-aminoacid gl
Keywords: موکوپلیساکاریدوز; LSD; lysosomal storage disease; CNS; central nervous system; BBB; blood-brain barrier; ERT; enzyme replacement therapy; GAG; glycosaminoglycans; CSF; cerebrospinal fluid; FDA; food and drug administration; ICV; intracerebroventricular; HLA; human leukocyt
Keywords: موکوپلیساکاریدوز; ER; endoplasmic reticulum; ERT; enzyme replacement therapy; FDA; U.S. Food and Drug Administration; LD; lysosomal disease; M6P; mannose-6-phosphate; M6PR; mannose-6-phosphate receptor; MPS; mucopolysaccharidosis; NPC; Type C Niemann-Pick disease; NPD; Typ
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Hearing loss; Audiologic evaluationMucopolissacaridose; Perda auditiva; Avaliação audiológica
Keywords: موکوپلیساکاریدوز; LSDs; lysosomal storage diseases; FD; Fabry disease; GD; Gaucher disease; LOPD; late onset Pompe disease; MPS; mucopolysaccharidosis; NBSP; newborn screening perception questionnaire; BIPQ; brief illness perception questionnaire; Newborn screening; Lysoso
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Tracheal stent; Airway stenosis; Bronchoscopy;
Keywords: موکوپلیساکاریدوز; Newborns; Glycosaminoglycans; Chondroitin sulfate; Heparan sulfate; Urine analysis; Mucopolysaccharidosis;
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Glycosaminoglycans; Growth factors; Bone disease; Fibroblast growth factor; Indian hedgehog;
Keywords: موکوپلیساکاریدوز; DAS; Difficult Airway Society; ERT; Enzyme replacement therapy; GAGs; Glycosaminoglycans; HSCT; Hematopoietic stem cell transplantation; MPS; Mucopolysaccharidosis; QoL; Quality of life; Mucopolysaccharidoses; Adult; Disease management; Lysosomal storage
Keywords: موکوپلیساکاریدوز; Enfermedades de depósito lisosomal; Enfermedad de Gaucher; Enfermedad de Fabry; Mucopolisacaridosis; Lysosomal storage disorders; Gaucher disease; Fabry disease; Mucopolysaccharidosis;
Keywords: موکوپلیساکاریدوز; MPS; mucopolysaccharidosis; ERT; enzyme replacement therapy; GAG; glycosaminoglycan;
Keywords: موکوپلیساکاریدوز; Hematopoietic cell transplantation; Mucopolysaccharidosis; Hurler syndrome
Keywords: موکوپلیساکاریدوز; antidrug antibody; elosulfase alfa; enzyme replacement therapy; immunogenicity; Morquio A syndrome; mucopolysaccharidosis;
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Alpha-fetoprotein; Amniotic fluid; Glycosaminoglycans
Keywords: موکوپلیساکاریدوز; Daidzein; γ-cyclodextrin; Fibroblasts; Hippocampal neuronal cells; Mucopolysaccharidosis; Glycosaminoglycans;
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Mesenchymal stem cell; Hematopoietic stem cells; Glycosaminoglycan; Differentiation;
Keywords: موکوپلیساکاریدوز; lysosomal storage disorders; Gaucher disease; mucopolysaccharidosis; mucolipidosis; pycnodysostosis; dysosotosis multiplex; bone involvement; bone crisis; osteoporosis; osteonecrosis;
Keywords: موکوپلیساکاریدوز; Sleep disturbances; Epilepsy; Mucopolysaccharidosis
Keywords: موکوپلیساکاریدوز; MPS; mucopolysaccharidosis; GAGs; glycosaminoglycans; DUFP; dried urine in filter paper; DS; dermatan sulfate; HS; heparan sulfate; KS; keratan sulfate; CS; chondroitin sulfate; DMB; 1,9-dimethylmethylene blue; Mucopolysaccharidoses; Glycosaminoglycans; D
Keywords: موکوپلیساکاریدوز; DBS; dried blood spot; GM1; gangliosidosis M1; LSDs; lysosomal storage disorders; MLD; metachromatic leukodystrophy; MPS; mucopolysaccharidosis; 4-MU; 4-methylumbelliferone; 4-MU-C3; 4-methylumbelliferyl-β-D-N,Nâ²,Nâ³-triacetylchitotrioside; 4-MU-dC2;
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Enzyme replacement; Echocardiography; Strain; Speckle tracking;
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Coronary artery; Glycosaminoglycan
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Pulmonary function tests; Impulse oscillometry; Whole body plethysmography
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Sanfilippo; Genistein; Treatment;
Keywords: موکوپلیساکاریدوز; CNS; Central nervous system; CsA; Cyclosporine; ELC; Early Learning Composite; ERT; Enzyme replacement therapy; HCT; Hematopoietic cell transplantation; IV; Intravenous; MPS; Mucopolysaccharidosis;
Keywords: موکوپلیساکاریدوز; %FVC; percent predicted forced vital capacity; 6MWT; six-minute walk test; Ab +; antibody positive; Ab â; antibody negative; AEs; adverse events; CSA; conformation-specific antibody assay; ELISA; enzyme-linked immunosorbent assay; FVC; forced vital ca
Keywords: موکوپلیساکاریدوز; cost-effectiveness; Hunter syndrome; iduronate-2-sulfatase; mucopolysaccharidosis
Natural history of echocardiographic abnormalities in mucopolysaccharidosis III
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Echocardiogram; Cardiac; Gene transfer;
Neurophysiology of hearing in patients with mucopolysaccharidosis type IV
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis IV; Auditory system; Electrophysiology; Audiological testing; Hearing impairment/loss; MPS; mucopolysaccharidosis; ABR; auditory brainstem response; DPOAE; distortion products of otoacoustic emission; MEMR; middle ear muscle reflex;
Delayed development of ossification centers in the tibia of prenatal and early postnatal MPS VII mice
Keywords: موکوپلیساکاریدوز; Mucopolysaccharidosis; Short stature; Murine models; Endochondral ossification; Primary ossification center; Secondary ossification center; Growth plate;
Composition and structure of glycosaminoglycans in DBS from 2-3-day-old newborns for the diagnosis of mucopolysaccharidosis
Keywords: موکوپلیساکاریدوز; Newborns; Dried blood spot; DBS; Glycosaminoglycans; Mucopolysaccharidosis; Chondroitin sulfate; Heparan sulfate; Hyaluronic acid;
Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5â¯years of treatment
Keywords: موکوپلیساکاریدوز; Morquio A; Mucopolysaccharidosis IVA; Long-term extension; Elosulfase alfa; 3MSCT; 3-min stair climb test; 6MWT; 6-min walk test; AE; adverse event; AUC0ât; area under the curve from time 0 to last measurable concentration; AUCinf; area under the curve
Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis
Keywords: موکوپلیساکاریدوز; Alpha-mannosidosis; Velmanase alfa; Enzyme-replacement therapy; Global treatment response model; OMIM 248500; Enzyme Commission number: 3.2.1.24; 3MSCT; 3-min stair climb test; 6MWT; 6-min walking test; BMI; body mass index; BOT-2; Bruininks-Oseretsky Tes
Genetic Infiltrative Cardiomyopathies
Keywords: موکوپلیساکاریدوز; Amyloidosis; Hemochromatosis; Cardiac oxalosis; Friedreich ataxia; Mucopolysaccharidosis; Fabry disease; Danon disease; PRKAG2 syndrome;
Metabolic Syndrome and Cardiovascular Risk Factors after Hematopoietic Cell Transplantation in Severe Mucopolysaccharidosis Type I (Hurler Syndrome)
Keywords: موکوپلیساکاریدوز; Metabolic syndrome; Hematopoietic cell transplantation; Mucopolysaccharidosis; Hurler syndrome; Dyslipidemia;
CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts
Keywords: موکوپلیساکاریدوز; Hurler syndrome; Mucopolysaccharidosis; Gene editing; CRISPR-Cas9;